AAPL 172.82 2.0791% MSFT 398.0952 0.7989% GOOG 168.0231 1.4816% GOOGL 166.28 1.4769% AMZN 184.96 3.3296% NVDA 854.77 2.9335% META 443.315 0.9392% TSLA 181.475 0.825% TSM 136.525 1.1746% LLY 758.37 -2.3663% V 268.64 0.4938% AVGO 1234.73 -0.6541% JPM 191.62 -0.1251% UNH 493.04 1.8446% NVO 125.14 -3.1499% WMT 59.8 1.6143% LVMUY 165.05 0.628% XOM 116.34 0.2672% LVMHF 826.0 0.4463% MA 441.05 -0.2307%
Last update at 2024-05-02T18:49:00Z
Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Income before tax | 551.47M | 530.76M | 81.70M | -5.85300M | -16.49800M |
Minority interest | -270.45800M | -287.21300M | 66.23M | 3.23M | 3.61M |
Net income | 490.66M | 469.25M | 88.97M | -5.20100M | -17.73100M |
Selling general administrative | 129.26M | 100.06M | 94.25M | 48.35M | 41.19M |
Selling and marketing expenses | - | - | - | - | - |
Gross profit | 714.04M | 658.68M | 204.45M | 76.29M | 63.07M |
Reconciled depreciation | 38.10M | 24.75M | 25.84M | 24.08M | 22.35M |
Ebit | 574.22M | 554.64M | 67.60M | 23.99M | 17.46M |
Ebitda | 568.40M | 543.67M | 93.43M | 48.51M | 39.81M |
Depreciation and amortization | -5.82000M | -10.97000M | 25.84M | 24.52M | 22.35M |
Non operating income net other | - | 0.28M | - | - | - |
Operating income | 574.22M | 554.64M | 67.60M | 23.99M | 16.44M |
Other operating expenses | 316.58M | 255.84M | 183.20M | 118.83M | 106.46M |
Interest expense | 20.41M | 30.26M | 30.74M | 29.96M | 27.40M |
Tax provision | 60.81M | 61.52M | 2.88M | -0.65200M | 0.42M |
Interest income | 2.34M | - | - | - | - |
Net interest income | -18.07600M | -30.26000M | -30.74000M | -29.95900M | -27.39900M |
Extraordinary items | - | - | - | - | - |
Non recurring | - | - | - | - | - |
Other items | - | - | - | - | - |
Income tax expense | 60.81M | 61.52M | 2.88M | -0.65200M | 0.42M |
Total revenue | 883.00M | 799.24M | 284.10M | 143.14M | 123.83M |
Total operating expenses | 147.63M | 115.28M | 103.55M | 51.98M | 45.69M |
Cost of revenue | 168.96M | 140.56M | 79.65M | 66.85M | 60.77M |
Total other income expense net | -22.74400M | -23.88000M | 14.10M | -29.84100M | -6.47400M |
Discontinued operations | - | - | - | - | - |
Net income from continuing ops | 490.66M | 469.25M | 78.82M | -5.20100M | -16.91500M |
Net income applicable to common shares | 220.21M | 182.04M | 76.89M | -8.48600M | -17.73100M |
Preferred stock and other adjustments | - | - | - | - | - |
Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Total assets | 2282.32M | 1918.28M | 1270.69M | 577.80M | 539.68M |
Intangible assets | 216.66M | 117.57M | 177.66M | 197.85M | 218.13M |
Earning assets | - | - | - | - | - |
Other current assets | 25.80M | 19.70M | 11.10M | 3.62M | 1.64M |
Total liab | 1377.07M | 1372.91M | 1115.94M | 433.17M | 391.66M |
Total stockholder equity | 545.22M | 315.50M | 88.51M | 141.40M | 144.41M |
Deferred long term liab | 2.20M | 2.70M | 3.40M | - | - |
Other current liab | 89.36M | 65.69M | 38.55M | 18.74M | 28.73M |
Common stock | 2.55M | 2.55M | 2.58M | 183.91M | 182.81M |
Capital stock | 2.55M | 2.55M | 2.58M | 183.91M | 182.81M |
Retained earnings | 404.77M | 184.56M | 0.85M | -42.38100M | -38.23700M |
Other liab | 693.38M | 713.64M | 400.36M | 15.90M | 18.35M |
Good will | 283.67M | 152.77M | 224.28M | 224.28M | 224.28M |
Other assets | 806.13M | 812.47M | 435.86M | 0.81M | 0.89M |
Cash | 632.14M | 551.27M | 236.18M | 24.70M | 21.87M |
Cash and equivalents | - | - | - | - | - |
Total current liabilities | 110.14M | 93.78M | 130.78M | 29.56M | 35.92M |
Current deferred revenue | 3.09M | 10.21M | 78.06M | 0.84M | 1.09M |
Net debt | -46.87600M | -16.95900M | 354.60M | 365.50M | 318.02M |
Short term debt | 11.71M | 9.72M | 6.00M | 2.50M | 2.50M |
Short long term debt | 5.44M | 6.00M | 6.00M | 2.50M | 2.50M |
Short long term debt total | 585.26M | 534.31M | 590.78M | 390.20M | 339.89M |
Other stockholder equity | 137.90M | 128.39M | 85.12M | 7.97M | 4.12M |
Property plant equipment | 116.59M | 46.33M | 101.31M | 94.31M | 42.58M |
Total current assets | 847.90M | 740.04M | 331.60M | 60.55M | 53.80M |
Long term investments | - | - | - | - | - |
Net tangible assets | 44.89M | 315.50M | -313.42000M | -280.73200M | -297.99700M |
Short term investments | - | - | - | - | - |
Net receivables | 146.81M | 117.51M | 51.02M | 18.03M | 15.99M |
Long term debt | 522.00M | 524.59M | 528.61M | 334.78M | 335.55M |
Inventory | 43.15M | 51.56M | 33.30M | 14.20M | 14.31M |
Accounts payable | 5.99M | 8.15M | 8.17M | 7.48M | 3.60M |
Total permanent equity | - | - | - | - | - |
Noncontrolling interest in consolidated entity | - | 229.86M | - | - | - |
Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
Accumulated other comprehensive income | - | - | -0.04400M | -0.13300M | -0.16700M |
Additional paid in capital | - | - | - | - | - |
Common stock total equity | - | 2.55M | 2.58M | 183.91M | 182.81M |
Preferred stock total equity | - | - | - | - | - |
Retained earnings total equity | - | 184.56M | - | - | - |
Treasury stock | - | - | - | - | - |
Accumulated amortization | - | - | - | - | - |
Non currrent assets other | 51.69M | 53.45M | 4.16M | 0.81M | 0.89M |
Deferred long term asset charges | - | - | - | - | - |
Non current assets total | 1434.41M | 1178.24M | 939.09M | 517.24M | 485.87M |
Capital lease obligations | 57.83M | 3.72M | 56.17M | 52.92M | 1.84M |
Long term debt total | - | 524.59M | - | - | - |
Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Investments | -267.61200M | 105.66M | 6.07M | -17.14800M | -3.45100M |
Change to liabilities | -8.70100M | -7.30200M | 78.40M | 2.55M | -1.67000M |
Total cashflows from investing activities | -267.61200M | 105.66M | 6.07M | -17.14800M | -3.45100M |
Net borrowings | -5.44000M | -6.00000M | 196.92M | -2.64000M | 55.43M |
Total cash from financing activities | -187.49900M | -159.04900M | 53.21M | -4.16700M | -9.16700M |
Change to operating activities | -23.56800M | -17.49100M | 9.74M | 1.52M | -12.33600M |
Net income | 490.66M | 469.25M | 78.82M | -5.20100M | -16.91500M |
Change in cash | 80.87M | 315.09M | 211.48M | 2.83M | -12.87300M |
Begin period cash flow | 551.27M | 236.18M | 24.70M | 21.87M | 34.74M |
End period cash flow | 632.14M | 551.27M | 236.18M | 24.70M | 21.87M |
Total cash from operating activities | 535.98M | 368.57M | 152.19M | 24.11M | -0.18600M |
Issuance of capital stock | 0.00000M | 0.00000M | 1758.93M | - | 0.00000M |
Depreciation | 38.10M | 24.75M | 25.84M | 24.08M | 22.35M |
Other cashflows from investing activities | -12.17300M | 120.50M | -12.17300M | -12.17300M | 0.16M |
Dividends paid | - | 153.45M | -609.32100M | 97.05M | 52.06M |
Change to inventory | 9.46M | -21.57400M | -19.09900M | 0.11M | 2.31M |
Change to account receivables | -22.27200M | -70.39100M | -33.14400M | -1.88800M | -4.14600M |
Sale purchase of stock | 0.00000M | 1.71M | -1457.98200M | - | 0.00000M |
Other cashflows from financing activities | -173.60400M | -153.04900M | 773.66M | -1.52700M | 298.09M |
Change to netincome | 319.96M | 45.83M | -0.34000M | 0.48M | -3.71800M |
Capital expenditures | 17.09M | 14.85M | 25.41M | 17.15M | 3.61M |
Change receivables | - | -70.39100M | - | - | - |
Cash flows other operating | - | -68.26000M | - | - | - |
Exchange rate changes | - | - | - | - | - |
Cash and cash equivalents changes | - | 315.18M | - | - | - |
Change in working capital | -45.08200M | -176.63100M | 35.89M | 2.29M | -15.84100M |
Stock based compensation | 18.67M | 10.46M | 24.63M | 1.68M | 2.12M |
Other non cash items | -8.69500M | -6.16300M | -7.52400M | 2.42M | 7.79M |
Free cash flow | 518.89M | 353.72M | 126.78M | 6.97M | -3.79700M |
Sector: Healthcare Industry: Biotechnology
Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
---|---|---|---|---|---|---|---|---|
MRVI Maravai Lifesciences Holdings Inc |
0.38 4.45% | 8.79 | 36.72 | 30.40 | 4.00 | 1.62 | 2.09 | 6.09 |
NVO Novo Nordisk A/S |
-4.07 3.15% | 125.14 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
NONOF Novo Nordisk A/S |
1.79 1.41% | 128.24 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
VRTX Vertex Pharmaceuticals Inc |
-1.13 0.28% | 401.01 | 30.40 | 24.75 | 10.68 | 6.25 | 9.52 | 20.36 |
CSLLY CSL Ltd |
1.06 1.19% | 90.20 | 42.45 | 26.95 | 7.05 | 5.80 | 7.85 | 26.51 |
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, Viral Clearance Prediction kits, and custom services. It serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
10770 Wateridge Circle, San Diego, CA, United States, 92121
Name | Title | Year Born |
---|---|---|
Mr. Carl W. Hull | Co-Founder and Exec. Chairman & Interim CEO | 1959 |
Mr. Kevin M. Herde | Exec. VP & CFO | 1972 |
Mr. Kurt Oreshack | Exec. VP, Gen. Counsel & Sec. | 1981 |
Ms. Christine Dolan | Chief Operating Officer of Biologics Safety Testing | 1968 |
Mr. Brian Neel | Chief Operating Officer of Nucleic Acid Production | 1976 |
Dr. Peter Michael Leddy Ph.D. | Exec. VP & Chief Admin. Officer | 1963 |
Ms. Debra Hart | Sr. Director of Investor Relations | NA |
Ms. Doreen Pippen | VP of Marketing | NA |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).